Neladalkib (NVL-655) Clinical Trials

2 actively recruiting trials across 2 locations

Filter by location:

Glendale, Arizona1 trial

Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

Palo Verde Hematology Oncology

Phase 3

Orange, California1 trial

A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)

University of California Irvine Medical Center

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.